View Clinical Trial (Medical Research Study)

Study of Escitalopram (Lexapro) for Improvement of Depressive Symptoms and Quality of Life in People With Multiple Sclerosis (MS) or Amyotrophic Lateral Sclerosis (ALS) Who Are Experiencing Depression - NCT00965497-20203(Clinical Trial 306867)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Columbia,
State:  
SC
Zip Code: 20203
Conditions: Major Depression - Multiple Sclerosis - Amyotrophic Lateral Sclerosis
Purpose: The purpose of this study is to see if escitalopram (Lexapro) improves symptoms of major depressive disorder in patients who have ALS or MS.
Study summary: This eight-week study aims to assess the effectiveness and tolerability of escitalopram in improving symptoms of Major Depression in patients with Amyotrophic Lateral Sclerosis (ALS) or Multiple Sclerosis (MS) as measured by the HAM-D. In addition, the study will assess improvement in the quality of life in patients with Major Depression and ALS or MS.
Criteria: Inclusion Criteria: - Patients between 18 and 70 years of age with documented ALS or MS, - DSM-IV episode of non-psychotic Major Depression, - ≥14 score on the 17-item HAM-D, - Ability to give informed consent. Exclusion Criteria: - History of psychotic disorders, - Psychotic depression, - Bipolar depression, - Suicide risk, - History of substance abuse in the previous 6 months, - History of unstable medical disorders, - Pregnancy or planning for pregnancy, - Severity of ALS or MS that limits participating in the study protocol.
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: February 2, 2010
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.